Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
News|Videos|November 10, 2025
Rezatapopt For Locally Advanced or Metastatic Solid Tumors With a TP53 Y220C Mutation: Initial Analysis of the Pivotal PYNNACLE Phase 2 Trial
Author(s)Alison Schram, MD
Alison M. Schram, MD, of Memorial Sloan Kettering Cancer Center, discusses initial results from the pivotal Phase 2 PYNNACLE trial evaluating rezatapopt, a first-in-class p53 reactivator, in patients with advanced solid tumors harboring a TP53 Y220C mutation.
Advertisement
Advertisement
Related to this article
The phase 3 REZILIENT3 trial met its primary end point at a pre-specified interim analysis, with a median PFS of 14.5 months and a 65.0% ORR.
CHMP has recommended EU approval of senaparib for advanced ovarian cancer based on FLAMES data.
The CHMP recommended perioperative pembrolizumab plus enfortumab vedotin for resectable muscle-invasive bladder cancer.
The FDA approved imlunestrant/abemaciclib for ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after progression on endocrine therapy.
Roswell Park Comprehensive Cancer Center unveiled a new and more compact mobile lung cancer screening unit.
The CHMP recommended approval of adjuvant T-DXd for HER2-positive early breast cancer with residual invasive disease after neoadjuvant therapy.
Udai S. Kammula, MD, FACS, discusses TIL therapy outcomes, the UMIS biomarker, and treatment implications in metastatic uveal melanoma.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Imlunestrant Plus Abemaciclib for ER+, HER2–, ESR1-Mutated Metastatic Breast Cancer
2
EU Approval Reccomended by CHMP for Senaparib in First-Line Advanced Ovarian Cancer
3
CHMP Backs Perioperative Pembrolizumab Plus Enfortumab Vedotin for Resectable MIBC
4
CHMP Recommends Adjuvant T-DXd for HER2+ Early Breast Cancer With Residual Invasive Disease
5